Table 1.
Participant characteristics
| Characteristic | Pre-intervention (n = 137) | Post-intervention (n = 132) | p-value |
|---|---|---|---|
| Sociodemographic | |||
| Age, median (IQR) | 80.0 (74.0–85.0) | 79.0 (73.0–84.0) | 0.40 |
| Male, n (%) | 92 (67.2) | 87 (65.9) | 0.82 |
| CALD, n (%) | 43 (31.4) | 39 (29.5) | 0.74 |
| Residential aged care resident, n (%) | 16 (11.7) | 21 (15.9) | 0.31 |
| Current or ex-smoker, n (%) | 78 (59.5) | 74 (57.4) | 0.72 |
| Clinical | |||
| Emergency admission, n (%) | 49 (35.8) | 58 (43.9) | 0.17 |
| Underwent operative management, n (%) | 109 (79.6) | 89 (67.4) | 0.02 |
| Open (vs endovascular only) procedure, n (%) | 55 (50.5) | 49 (55.1) | 0.52 |
| Emergency (vs elective) procedure, n (%) | 26 (23.9) | 32 (36.0) | 0.06 |
| Charlson Comorbidity Index score, median (IQR) | 3.0 (2.0–5.0) | 3.0 (1.0–4.0) | 0.54 |
| Diabetes mellitus, n (%) | 62 (45.3) | 60 (45.5) | 0.97 |
| Renal impairment, n (%) | 41 (29.9) | 41 (31.1) | 0.84 |
| Pre-existing or new diagnosis of peripheral arterial disease | 83 (60.6) | 75 (56.8) | 0.53 |
| Pre-existing hypertension | 113 (82.5) | 102 (77.3) | 0.29 |
| Cardiovascular disease | 80 (58.4) | 89 (67.4) | 0.13 |
| No. of regular medications, median (IQR) | 7.0 (5.0–9.5) | 9.0 (6.0–12.0) | <0.001 |
| Geriatric syndromes | |||
| Frail (CFS >4), n (%) | 41 (29.9) | 54 (40.9) | 0.06 |
| Functional dependence (in ≥1 ADL), n (%) | 44 (32.1) | 46 (34.8) | 0.64 |
| Cognitive impairment (dementia diagnosis or AMTS score < 8), n (%) | 47 (36.7) | 40 (32.5) | 0.48 |
| Assisted mobility, n (%) | 17 (12.4) | 19 (14.4) | 0.63 |
| History of falls, n (%) | 49 (35.8) | 59 (44.7) | 0.14 |
| Polypharmacya (> 4 regular medications) | 113 (82.5) | 112 (84.8) | 0.60 |
ADL activities of daily living, AMTS Abbreviated Mental Test Score, CALD culturally and linguistically diverse, CFS Clinical Frailty Score, IQR interquartile range
aPolypharmacy was defined as the use of five or more regularly administered medications, excluding vitamins and mineral supplements, ‘as required’ medications and medications administered via topical, vaginal, rectal, nasal, otic or ophthalmological routes